<DOC>
	<DOC>NCT01903213</DOC>
	<brief_summary>To evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.</brief_summary>
	<brief_title>Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Chronic renal failure patients with Hyperphosphatemia receiving peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>Bixalomer</keyword>
	<keyword>Chronic renal failure patients with Hyperphosphatemia</keyword>
	<keyword>Kiklin®</keyword>
</DOC>